[Supplementary antiblastic polychemotherapy in localized malignant bone tumors. I. Ewing's sarcoma and osteosarcoma].
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003609:Dactinomycin / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D012516:Osteosarcoma / Q000188:drug therapy* / Q000601:surgery; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000601:surgery; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate
La polichemioterapia antiblastica complementare nei tumori ossei maligni localizzati. I. Sarcoma di Ewing ed osteosarcoma